全文获取类型
收费全文 | 222篇 |
免费 | 30篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
妇产科学 | 5篇 |
基础医学 | 22篇 |
口腔科学 | 3篇 |
临床医学 | 18篇 |
内科学 | 32篇 |
皮肤病学 | 3篇 |
神经病学 | 37篇 |
特种医学 | 6篇 |
外科学 | 29篇 |
综合类 | 1篇 |
预防医学 | 51篇 |
眼科学 | 2篇 |
药学 | 20篇 |
肿瘤学 | 21篇 |
出版年
2023年 | 2篇 |
2022年 | 1篇 |
2021年 | 4篇 |
2020年 | 3篇 |
2019年 | 8篇 |
2018年 | 9篇 |
2017年 | 17篇 |
2016年 | 5篇 |
2015年 | 9篇 |
2014年 | 7篇 |
2013年 | 12篇 |
2012年 | 11篇 |
2011年 | 15篇 |
2010年 | 8篇 |
2009年 | 8篇 |
2008年 | 21篇 |
2007年 | 21篇 |
2006年 | 10篇 |
2005年 | 19篇 |
2004年 | 7篇 |
2003年 | 10篇 |
2002年 | 13篇 |
2001年 | 3篇 |
2000年 | 2篇 |
1999年 | 2篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1994年 | 3篇 |
1993年 | 4篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1987年 | 1篇 |
1985年 | 3篇 |
1982年 | 1篇 |
1966年 | 2篇 |
1960年 | 1篇 |
排序方式: 共有252条查询结果,搜索用时 15 毫秒
1.
Kragh Thomsen M. Rasmussen M. Fuursted K. 《世界核心医学期刊文摘》2006,2(9):2-22
2000年11月,作者得知从Aarhus大学医院皮肤科患者分离到的金黄色葡萄球菌对苯唑西林出现界线耐药(BORSA)。本文旨在描述其表型和基因型,并评估可能的传播途径以干预和阻止进一步蔓延。菌株由脉冲场凝胶电泳鉴定。几个感染控制方案的缺口显示患者间可直接或间接传播。皮肤屏障缺陷、皮肤病患者金黄色葡萄球菌的高携带率和院内双氯西林的高消耗率可促使传播。改善普通感染控制措施和重新评价院内抗生素政策后,该菌的暴发感染消失。 相似文献
2.
3.
Per Kragh Andersen Maja Pohar Perme Hans C. van Houwelingen Richard J. Cook Pierre Joly Torben Martinussen Jeremy M. G. Taylor Michal Abrahamowicz Terry M. Therneau 《Statistics in medicine》2021,40(1):185-211
This paper provides guidance for researchers with some mathematical background on the conduct of time‐to‐event analysis in observational studies based on intensity (hazard) models. Discussions of basic concepts like time axis, event definition and censoring are given. Hazard models are introduced, with special emphasis on the Cox proportional hazards regression model. We provide check lists that may be useful both when fitting the model and assessing its goodness of fit and when interpreting the results. Special attention is paid to how to avoid problems with immortal time bias by introducing time‐dependent covariates. We discuss prediction based on hazard models and difficulties when attempting to draw proper causal conclusions from such models. Finally, we present a series of examples where the methods and check lists are exemplified. Computational details and implementation using the freely available R software are documented in Supplementary Material. The paper was prepared as part of the STRATOS initiative. 相似文献
4.
5.
6.
Jonathan I. Silverberg Emma Guttman-Yassky Melinda Gooderham Margitta Worm Stephanie Rippon Sean O’Quinn René van der Merwe Nana Kragh Azra Kurbasic Andreas Wollenberg 《Annals of allergy, asthma & immunology》2021,126(5):576-583.e4
BackgroundAtopic dermatitis (AD) is associated with a substantial burden on quality of life (QoL).ObjectiveTo evaluate the effects of tralokinumab on health-related QoL in patients with moderate-to-severe AD using patient-reported outcomes.MethodsThis was a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study in adults with moderate-to-severe AD. The patients received subcutaneous tralokinumab or placebo (1:1:1:1) every 2 weeks for 12 weeks and class 3 topical corticosteroid cream or ointment at least once daily from the run-in to end of follow-up. Patient-reported outcome end points were change from baseline to week 12 in the Dermatology Life Quality Index (dermatology life quality index (DLQI); prespecified secondary objective), the Short Form 36 Health Survey (SF-36) version 2, and sleep interference numeric rating scale score (prespecified exploratory objectives).ResultsA total of 204 patients were randomized to placebo (n = 51) or tralokinumab (45 mg, n = 50; 150 mg, n = 51; 300 mg, n = 52). Tralokinumab 300 mg every 2 weeks improved total Dermatology Life Quality Index vs placebo at week 12 (placebo-adjusted mean change, ?3.51 [95% confidence interval, ?6.00 to ?1.02]). At week 12, both the mental component summary (4.23 [0.98-7.47]) and the physical component summary (4.26 [1.83-6.69]) and all 8 domains of the Short Form 36 Health Survey were improved in patients treated with tralokinumab 300 mg vs placebo. Sleep interference was improved at week 12 with all tralokinumab doses vs placebo.ConclusionTralokinumab improved health-related QoL in patients with moderate-to-severe atopic dermatitis, providing further evidence of the value of targeting interleukin-13 in such patients.Trial RegistrationClinicalTrials.gov identifier: NCT02347176; https://clinicaltrials.gov/ct2/show/NCT02347176. 相似文献
7.
Kim Krogsgaard Erik Christensen Niels Bindslev Solko Schalm Per Kragh Andersen Helmer Ring-Larsen European Concerted Action on Viral Hepatitis 《Journal of hepatology》1996,25(6):795-802
Background/Aims: Alpha interferon (IFN) is an established treatment of chronic hepatitis B. The effect has been shown to be dose related, recommended dose regimens being associated with a doubling of the spontaneous, baseline HBeAg to anti-HBe seroconversion rate. However, the efficacy of IFN treatment in relation to the dose of IFN actually received remains to be established. The aim of this study was to estimate the relative efficacy of IFN as a function of the cumulative IFN dose. In addition we determined if and when a patient returns to his baseline chance of seroconversion after stopping IFN therapy.Materials and Methods: Individual patient data from 10 clinical controlled trials were available for the present analysis, in all, 746 patients, of whom 491 received IFN and 255 were untreated controls. The data were analyzed performing a time-dependent Cox regression analysis of the relative efficacy of IFN using the cumulative IFN dose administered up to any given time during the observation period and the time after termination of therapy as explanatory variables.Results: In the proposed model, the chance of HBeAg disappearance for a treated patient relative to no therapy was estimated to 2.1 at a cumulative dose of 100 MU and leveled out at about 2.8 at a cumulative dose of 500 MU. The effect of IFN was shown to decay repidly after discontinuation and after 3 months a patient could be considered to be back to his baseline chance of HBeAg disappearance. These findings show that IFN administered at a dose of 15–30 MU/week should be considered effective (relative efficacy≈2) already after 1–2 months of treatment.Conclusions: The present findings do not lend any support to the concept that IFN treatment becomes less effective when a certain total dose of IFN has been administered or that the treatment effect reaches beyond 3 months after stopping IFN. 相似文献
8.
9.
AbstractBackground and aim: During recent years, there has been an increased focus on reducing use of mechanical restraint in psychiatric care. Studies show that implementing an assessment tool could potentially prevent or decrease the number of episodes of mechanical restraint. This study aims to examine the association between use of the Danish assessment tool for psychiatric inpatients diagnosed with mania (MAS-M) and mechanical restraint to highlight if number, type, and duration of restraint could be prevented or reduced by this procedure.Materials and method: This historical cohort study included psychiatric inpatients diagnosed with bipolar disorder and hospitalized with symptoms of mania at the departments of affective disorders during the years 2012–2015. Logistic regression was used in the statistical analyses.Result: A total of 218 patients were included, 74 of whom were scored with MAS-M. Thirty-five episodes of mechanical restraint were recorded. A crude OR of 1.58 (95% CI: 0.75–3.30) of the association was estimated. The study showed a tendency toward patients scored with MAS-M being more frequently restrained with both belt and straps, however, in shorter duration, compared to the control group.Conclusion: This study reported relevant clinical information concerning staff’s use of MAS-M, however, did not show a significant association between the use of MAS-M and mechanical restraint. Nevertheless, conflicting results about the impact of MAS-M on preventing and reducing these coercive measures have been highlighted, suggesting that more complex factors influence the use of mechanical restraint. No causal effect was examined thus further studies are needed. 相似文献
10.
Penicillin G Treatment in Infective Endocarditis Patients – Does Standard Dosing Result in Therapeutic Plasma Concentrations?
下载免费PDF全文
![点击此处可从《Basic & clinical pharmacology & toxicology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Kristina Öbrink‐Hansen Henrik Wiggers Bo Martin Bibby Tore Forsingdal Hardlei Kaare Jensen Marianne Kragh Thomsen Birgitte Brock Eskild Petersen 《Basic & clinical pharmacology & toxicology》2017,120(2):179-186
Penicillin G is frequently used to treat infective endocarditis (IE) caused by streptococci, penicillin‐susceptible staphylococci and enterococci. Appropriate antibiotic exposure is essential for survival and reduces the risk of complications and drug resistance development. We determined penicillin G plasma concentration [p‐penicillin] once weekly in 46 IE patients. The aim was to evaluate whether penicillin G 3 g every 6 hr (q6 h) resulted in therapeutic concentrations and to analyse potential factors that influence inter‐ and intra‐individual variability, using linear regression and a random coefficient model. [P‐penicillin] at 3 hr and at 6 hr was compared with the minimal inhibitory concentration (MIC) of the bacteria isolated from blood cultures to evaluate the following PK/PD targets: 50% fT > MIC and 100% fT > MIC. [P‐penicillin] varied notably between patients and was associated with age, weight, p‐creatinine and estimated creatinine clearance (eCLcr). Additionally, an increase in [p‐penicillin] during the treatment period showed strong correlation with age, a low eCLcr, a low weight and a low p‐albumin. Of the 46 patients, 96% had [p‐penicillin] that resulted in 50% fT > MIC, while 71% had [p‐penicillin] resulting in 100% fT > MIC. The majority of patients not achieving the 100% fT > MIC target were infected with enterococci. Streptococci and staphylococci isolated from blood cultures were highly susceptible to penicillin G. Our results suggest that penicillin G 3 g q6 h is suitable to treat IE caused by streptococci and penicillin‐susceptible staphylococci, but caution must be taken when the infection is caused by enterococci. When treating enterococci, therapeutic drug monitoring should be applied to optimize penicillin G dosing and exposure. 相似文献